The diagnosed incidence of small intestine neuroendocrine tumors (SI-NETs) is increasing, and the underlying genomic mechanisms have not yet been defined. Using exome- and genome-sequence analysis of SI-NETs, we identified recurrent somatic mutations and deletions in CDKN1B, the cyclindependent kinase inhibitor gene, which encodes p27. We observed frameshift mutations of CDKN1B in 14 of 180 SI-NETs, and we detected hemizygous deletions encompassing CDKN1B in 7 out of 50 SI-NETs, nominating p27 as a tumor suppressor and implicating cell cycle dysregulation in the etiology of SI-NETs.
The diagnosed incidence of small intestine neuroendocrine tumors (SI-NETs) is increasing, and the underlying genomic mechanisms have not yet been defined. Using exome- and genome-sequence analysis of SI-NETs, we identified recurrent somatic mutations and deletions in CDKN1B, the cyclindependent kinase inhibitor gene, which encodes p27. We observed frameshift mutations of CDKN1B in 14 of 180 SI-NETs, and we detected hemizygous deletions encompassing CDKN1B in 7 out of 50 SI-NETs, nominating p27 as a tumor suppressor and implicating cell cycle dysregulation in the etiology of SI-NETs.
NETs are rare neoplasms (~1 per 100,000 in the United States) that are thought to arise from endocrine precursor cells and occur most commonly in the lung, pancreas and small intestine 1 . Well-differentiated NETs are typically more indolent than other epithelial malignancies but can nevertheless metastasize 1 . Both germline and somatic mutations of MEN1, the multiple endocrine neoplasia type 1 gene, are common in lung and pancreatic NETs 1 . Pancreatic NETs are also characterized by recurrent somatic mutations in DAXX, ATRX, PTEN and TSC2 (ref. 2) . In SI-NETs, by contrast, evidence for focal events that are indicative of driver alterations has remained inconclusive; hemizygous loss of chromosome 18 is the most frequent known genomic event, followed by arm-level gains of chromosomes 4, 5, 14 and 20 (refs. 3-5) . Recently, a whole-exome sequencing study of 48 SI-NETs examining somatic single nucleotide variants (SSNVs) identified mutations in several cancer genes, although none were recurrently altered 5 .
To identify genomic alterations driving tumorigenesis in SI-NETs, we profiled 55 tumors from 50 individuals using a combination of whole-exome and whole-genome sequencing ( Fig. 1a and Supplementary Tables 1-5 ). Mutation analysis of the exome sequencing data with the MuTect algorithm 6,7 identified a total of 1,230 genes with somatic mutations, 90% of which (1,113/1,230) were mutated in only a single individual. We observed a relatively low non-silent SSNV rate of 0.77 per Mb (range, 0.13-2.51 per Mb) (Fig. 1a, Supplementary Fig. 1a and Supplementary Table 6 ). Of the 1,230 genes that were mutated in our study, 21 were also found to be mutated in the previous SI-NET study and another 17 were mutated in a pancreatic NET study, including the cancer census genes ATRX and COL1A1, each in a single individual (Supplementary Fig. 1b-d) 2, 5, 8 . The lack of substantial overlap in recurrently altered genes suggests that many of the mutations are passengers. There are potentially therapeutically targetable mutations in several genes, including SRC, FYN, KDR and IDH1 (encoding p.Arg132His); however, each was only present within a single individual (Supplementary Table 6 ).
We identified significantly mutated genes by measuring nucleotideand sample-specific mutation rates in the SI-NET sequence data, computing an expected gene-specific mutation frequency for the SI-NETs on the basis of the size and nucleotide composition of each gene and then comparing the actual mutation frequency for each Somatic mutation of CDKN1B in small intestine neuroendocrine tumors 1 4 8 4 VOLUME 45 | NUMBER 12 | DECEMBER 2013 Nature GeNetics l e t t e r s gene to the calculated expected number 9 . This analysis of the 50 cases identified statistically significant mutations in only one gene, the cell cycle regulator CDKN1B (P = 6.5 × 10 −10 ). In total, we found small insertions and deletions within CDKN1B in 10% (5/50) of the cases (Fig. 1a and Supplementary Table 7) , which lead to frameshift mutations (Fig. 1b) . We validated these mutations by independent PCR and sequencing. Furthermore, copy number analysis identified hemizygous deletions encompassing CDKN1B in seven cases ( Fig. 1c  and Supplementary Table 8 ). Four out of these seven SI-NETs harboring CDKN1B deletions retained both copies of chromosome 18 compared to 8 out of 35 SI-NETs without CDKN1B deletions (P = 0.048, two-tailed Fisher's exact test). The region encompassing CDKN1B, at 12p13, is frequently hemizygously deleted in ovarian, prostate and non-small cell lung cancers and multiple hematological malignancies [10] [11] [12] [13] [14] [15] [16] .
To confirm the incidence of CDKN1B mutations in SI-NETs, we analyzed two independent cohorts: 48 SI-NETs reported by Banck et al. 5 and an extension set of 81 SI-NETs sequenced to a mean 800-fold coverage at CDKN1B. We detected two previously unreported somatic deletions within CDKN1B in the Banck et al. 5 cohort that were not previously analyzed for insertions or deletions (indels) 5 , both of which result in frameshift mutations. Analysis of the extension cohort identified seven small indels within CDKN1B that lead to frameshifts; the extension set did not have paired germline DNA, so we cannot exclude the possibility that some of these inactivating alterations are germline. Overall we detected heterozygous frameshift mutations in CDKN1B in 8% (14/180) of the individuals analyzed.
The presence of heterozygous inactivating mutations in CDKN1B is consistent with the possibility that CDKN1B acts as a haploinsufficient tumor-suppressor gene in SI-NETs. One possible explanation is that some expression of p27 is necessary for cell proliferation, as has been described in certain oncogenic models 17, 18 , thus making biallelic deletion disfavored. Several cancer genes that are recurrently mutated, including FBXW7, PTEN, DICER1 and CREBBP, were recently reported to be haploinsufficient tumor suppressors in mouse genetic models of cancer [19] [20] [21] [22] . The increased susceptibility to tumors after DNA damage that is observed in Cdkn1b heterozygous knockout mouse models along with elevated cellular proliferation [23] [24] [25] [26] is consistent with the hypothesis that CDKN1B is haploinsufficient for tumor suppression.
We found hemizygous loss of chromosome 18 (log 2 (copy number/2) < −0.1) in ~78% (43/55) of SI-NETs, but this loss was associated with only a slight increase in the mutation rate genome wide ( Supplementary Figs. 2 and 3) . We found two genes, including BCL10, which is mutated in colorectal cancer 27 , to be altered exclusively in the 12 cases with diploid chromosome 18 ( Supplementary Fig. 3d ). Because of the high frequency of hemizygous deletion of chromosome 18, we examined the cohort for somatic mutations to growth-inhibitory or 'STOP' 28 genes within the three frequently deleted regions of this chromosome. Although we observed no somatic mutations, it is possible that hemizygous loss of these genes may contribute to SI-NET tumorigenesis through altered gene dosage (Supplementary Table 9 ). In addition, comparison with genes that are mutated in small cell lung cancer 29, 30 , a tumor type that shares neuroendocrine characteristics with SI-NETs, showed 199 genes with mutations in common in both c b A4_TP  D187_TP  T9_TP  D192_TM  T8_TM  H15_TP  T10_TM  H26_TP  H52_TP  D183_TM  T7_TP  T6_TM  D2810_TP  A11_TP  H5_TP  D188_TP  A14_TM  H6_TM  D195_TP  A17_TP  A16_TP  A12_TM  H58_TM  H62_TP  A7_TM  B8_TM  B17_TP  B11_TP  H61_TP  B4_TP  B2_TM  H54_TP  H55_TP  H56_TM  H57_TP  H7_TP  B1_TM  B13_TM  A6_TM  T3_TP  H10_TM  A9_TM  H27_TM  H32_TP  B14_TP  B15_TP npg l e t t e r s studies; however, this overlap may be due to the high overall mutation rate in small cell lung cancer rather than a shared mechanism of tumorigenesis ( Supplementary Fig. 4 and Supplementary Tables 10 and 11 ).
To survey for genomic rearrangements, we performed whole-genome sequencing on 24 tumor-normal sample pairs. The number of somatic rearrangements detected by paired-end and split-read mapping 31, 32 ranged from 0 to 45 per case, with a median of 7 ( Supplementary Fig. 5 and Supplementary  Table 12 ). Of those rearrangements, 20% (33/163) involved genes or promoter regions, leading to five potential fusion proteins and two in-frame deletions; however, none of these rearrangements was recurrent (Supplementary Table 13 ). The concordance of SSNVs identified through whole-genome and whole-exome sequencing was ~95% on average when sufficient coverage was available 6 .
Tumor heterogeneity within epithelial tumors can be exceptionally complex, and cells shed from the primary tumor can form distant metastases 33 . Approximately 25% of SI-NETs are multifocal tumors at the time of resection, and 10-15% of neuroendocrine metastases are diagnosed as being of unknown primary origin 34, 35 . When we compared exomic mutations and copy number data for paired primary and metastatic tumors, we observed no overlap in SSNVs or somatic copy number alterations between the primary tumor and metastasis in two out of five primary-metastatic-normal trios ( Fig. 2  and Supplementary Table 14) . We confirmed that germline SNPs were concordant in the trios to exclude sample mix up. In one particular case (A16), the primary tumor contained a CDKN1B frameshift mutation and the metastasis did not, a phenomenon that has also been reported for PIK3CA and EGFR in breast and non-small cell lung cancer, respectively 36, 37 . It is hypothesized that the metastases in these two cases may have been derived from an undiagnosed independent primary lesion, a subclonal population that was not detected by sequencing or a clone that was shed from the primary tumor early in the progression and before the acquisition of major genomic events. In contrast, Banck et al. 5 assessed the overlap of 35 gene mutations in paired primary and metastasis samples and observed an 83% concordance in five cases. Given the small number of primary-metastaticnormal SI-NET trios (five cases each) in our two cohorts, the difference between these data sets is consistent with statistical fluctuation. A Fisher's exact test comparing a case series with two primarymetastatic discordances and three concordances to a case series with five primary-metastatic somatic mutation concordances and no discordances yielded P = 0.22, which is consistent with the null hypothesis that the two data sets are identical. This suggests that SI-NETs are observed in a population in which a subset of patients may harbor multifocal tumors and another subset may harbor unifocal tumors.
The discordance between primary tumors and metastasis, along with the multifocal nature of SI-NETs, highlights a challenge in identifying underlying driving events in these tumors.
Somatic mutations targeting the cell cycle regulatory gene CDKN1B were the most frequent gene-specific events in SI-NETs. CDKN1B encodes a cyclin-dependent kinase inhibitor that binds to and inhibits CDK2 and CDK4 (refs. 38,39) . Mouse models of Cdkn1b haploinsufficiency have larger body and organ size and enhanced sensitivity to mitogenic stimulation owing to greater Cdk2 activity [23] [24] [25] . In contrast to CDKN2A and related genes encoding inhibitors of CDK4-CDK6, somatic mutations in CDKN1B were recently reported at a low frequency in breast and prostate cancers 16, 40, 41 . CDKN1B is also known as MEN4 and is mutated in the germline of families with a phenotype of MEN-1 syndrome without an identifiable mutation in MEN1 (ref. 42) . Furthermore, menin, the product of MEN1, associates with promoter regions to mediate the expression of CDKN1B and CDKN2C through epigenetic regulation 43, 44 .
In summary, we present a comprehensive genomic analysis of somatic variants and whole genomes of SI-NETs. SI-NETs are dominated by large, arm-level copy number gains and losses, but we found strikingly few recurrent somatic gene alterations. The discovery of recurrent CDKN1B mutations raises the possibility that the p21-p27-p57 family proteins may be haploinsufficient tumor suppressors and suggests a focus on cell cycle regulation in understanding the pathogenesis of SI-NETs.
METhodS
Methods and any associated references are available in the online version of the paper.
Accession codes. Whole-exome sequencing of 55 SI-NETs and wholegenome sequencing of 24 SI-NETs in this study have been deposited in the dbGaP repository under accession code phs000579.v1.p1. 
npg oNLINE METhodS
Sample collection and preparation. Anonymized tumor specimens and clinical information were collected after obtaining written, informed consent and were processed using protocols approved by the Institutional Review Boards of the Dana-Farber Cancer Institute, the Broad Institute and the Cooperative Human Tissue Network, the Research Ethics Board of the University Health Network and the National Health Services Research Ethics Board. A total of 55 tumors from 50 individuals were analyzed in this study by whole-genome and whole-exome sequencing (Supplementary Tables 1 and 2) . Germline SNP analysis was performed on tumor-normal and metastatic-normal pairs to confirm the identities. A single sample was removed from the cohort because it did not match its normal pair.
Whole-exome sequencing. The generation of sequencing data was performed using a protocol that has been detailed previously 31, 32, 45 . In brief, exonic regions were captured using the Agilent V2 capture probe set and sequenced by 76-bp paired-end reads using Illumina HiSeq2000 instruments. A median of 9.15 Gb of unique sequence data were generated for each sample, 91% of which were aligned to the target exome using the Burrows-Wheeler Aligner (BWA) 46 , resulting in a median coverage of each base of 140× (Supplementary Table 3 ).
Whole-genome sequencing. Genomic DNA from 23 tumor-normal pairs was sent to Axeq Technologies for whole-genome library construction and sequencing. Genomic DNA was sheared to an average size of 400 bp, and libraries were prepared following the Illumina TruSeq protocol. Each library was sequenced on an Illumina HiSeq2000 to generate 101-bp paired-end reads. Each whole-genome library was sequenced to generate 108 Gb of raw data with a mean depth of 30× alignable coverage (Supplementary Table 4) .
Variant calling. Downstream sequencing analysis was performed as described 6, 32 . Before mutation and indel calling, sequencing reads were locally realigned to improve the detection of indels and decrease the number of false-positive SNVs caused by misaligned reads, particularly at the 3′ end 47 . For mutation detection, >14 reads in the tumors and >8 reads in the normal samples were necessary to call candidate somatic base substitutions, and indels were detected using MuTect 6 . Germline mutations were detected using the UnifiedGenotyper 47 . All somatic mutations were manually reviewed and visually confirmed with the Integrated Genomics Viewer (http:// www.broadinstitute.org/igv/).
Extension cohort and validation sequencing.
Approximately 100-200 ng of DNA was used as the template for a multiplex PCR reaction tiling CDKN1B using the Fluidigm Access Array microfluidic device. PCR products were barcoded and pooled in sets of 48 samples and subjected to Illumina sequencing on MiSeq to a mean coverage of 800×. Reads were aligned to hg19 using BWA and analyzed as previously described 48 .
CDKN1B indel calling in the Banck et al. 5 cohort. The whole-exome sequencing files from the current study and the study by Banck et al. 5 were run through the Strelka algorithm 49 to identify indels. The Strelka algorithm identified 100% of the CDKN1B indels identified with the MuTect algorithms 6 .
Copy number profiling. DNA from 61 samples was hybridized to Affymetrix SNP6.0 arrays using standard approaches. Raw data were preprocessed, normalized and segmented as previously described in detail 32 . Segmented copy number data were visualized using the Integrated Genomics Viewer (http://www.broadinstitute.org/igv). Segmented copy number profiles were generated from whole-exome sequencing using the SegSeq algorithm 50 .
To analyze segmented copy number profiles, the GISTIC 2.0 algorithm was used to identify arm-level and focal regions of copy number alterations as described 51 . A length threshold of 80% of a chromosome arm was used to distinguish between arm-level and focal events. To remove false-positive segments resulting from hypersegmentation, we further filtered segments using an amplitude threshold at a copy difference of 0.1. The frequencies of samples with chromosome arms displaying gains (relative copy number >2.1) and losses (relative copy number <1.1) are shown for each chromosome arm. The output of focal GISTIC was used to define the key peaks of amplification and deletion ( Supplementary Fig. 2 and Supplementary  Tables 15 and 16 ).
